Dyne Therapeutics (DYN) Accumulated Expenses (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Accumulated Expenses data on file, last reported at $29.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 34.29% year-over-year to $29.2 million in Q1 2026; TTM through Mar 2026 was $29.2 million, a 34.29% increase from a year earlier, with the FY2025 full-year figure at $17.1 million, up 30.56% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $29.2 million, up from $17.1 million in the prior quarter.
• Over the last five years, Accumulated Expenses for DYN reached as high as $29.2 million in Q1 2026 and fell as low as $1.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $11.6 million across 5 years, with a median of $10.4 million in 2024.
• Across the five-year window, Accumulated Expenses sank 71.46% in 2022 and soared 518.9% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $5.9 million in 2022, then surged by 294.93% to $23.4 million in 2023, then tumbled by 44.13% to $13.1 million in 2024, then jumped by 30.56% to $17.1 million in 2025, then surged by 70.85% to $29.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $29.2 million in Q1 2026, $17.1 million in Q4 2025, and $13.2 million in Q3 2025.